AG
KPTI icon

Algert Global’s Karyopharm Therapeutics KPTI Stock Holding History

Algert Global’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,788
Closed -$338K – 1170
2023
Q1 		$338K Buy
5,788
+277
+5% +$13.7K 0.02% 917
2022
Q4 		$281K Sell
5,511
-886
-14% -$61.4K 0.02% 941
2022
Q3 		$524K Sell
6,397
-3,042
-32% -$227K 0.03% 788
2022
Q2 		$639K Buy
+9,439
New +$866K 0.05% 673
2022
Q1 		– Sell
-5,216
Closed -$503K – 1252
2021
Q4 		$503K Sell
5,216
-620
-11% -$61.8K 0.06% 530
2021
Q3 		$509K Buy
5,836
+3,415
+141% +$355K 0.07% 531
2021
Q2 		$375K Buy
+2,421
New +$351K 0.13% 231

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Algert Global's KPTI Position: Q2 2023 in Review

Algert Global sold out of Karyopharm Therapeutics (KPTI) in Q2 2023, closing a stake of 5,788 shares — an estimated $338K sold.

Algert Global first reported a position in KPTI in Q2 2021 and held it in 7 quarters. The position peaked at $639K in Q2 2022. 137 funds tracked by Wall St. Rank hold KPTI as of Q2 2023.

  • Algert Global reported no remaining Karyopharm Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Algert Global sold 5,788 Karyopharm Therapeutics shares in Q2 2023, an estimated $338K.
  • Algert Global first reported a position in Karyopharm Therapeutics in Q2 2021 and held it in 7 quarters.
  • Algert Global's Karyopharm Therapeutics position peaked at $639K in Q2 2022.
  • 137 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2023.

Based on Algert Global's 13F filing for Q2 2023, filed 14 Aug 2023.